Funded Tech Companies

Expedition Therapeutics

Looking for the VC firms that provided funding to Expedition Therapeutics? Balyasny Asset Management, General Atlantic and Adage Capital Management joined the equity holders in this biopharmaceutical company.

Company Overview

Contact Information

Company Background Information

Overview

At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our therapy is designed to target neutrophilic inflammation, a novel and clinically validated pathway that is a major driver of tissue damage, airway remodeling, and progressive decline in lung function. Our lead candidate, EXPD-101, is a potent, oral, once-daily DPP1 inhibitor being developed for COPD, with the potential to deliver continuing improvement for millions of patients who currently have no disease-controlling treatment options.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

8/5/2026

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Yi Larson

        

Chief Medical Officer

Geoff Gilmartin

        

VP - Bus. Development

Eric Hu

        

Company Investors

• Balyasny Asset Management
• General Atlantic
• Adage Capital Management
• BVF Partners
• Vivo Capital
• Forbion Capital Partners
• Sanofi Ventures
• Venrock Healthcare Capital Partners
• Sofinnova Partners
• Logos Capital
• RA Capital
• Dawn Biopharma
• Novo Holdings

Browse more funded tech companies:

Expedia | Expeditors International

Share this article

About Our Venture Capital Database

Our data comes from VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary